Origin Bio blog · Mar 2026
Releases 10,000 AI-designed proximal enhancer-like sequences across three cell types with predicted activity, TF-binding annotations, quality metrics, and 3D structures on Switch.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Origin Bio is a San Francisco biotech startup founded in 2025 and backed by Y Combinator Winter 2026. It builds a tissue-first cancer biology platform that maps patient tumors with spatial, molecular, and functional readouts, and trains multimodal AI models (including Axis) to improve target discovery, perturbation-response prediction, and safer cell/gene therapy design.
Primary product
A tissue-first cancer biology platform plus the Axis multimodal AI model for regulatory DNA design and prediction.
Founded
2025
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Computational biology / drug discovery
Offices
Open Positions
0 jobs at Origin
No open positions
Check back later for new openings